Author

L. Fazli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 4 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

M. E. Gleave· 4 shared X. Dong· 3 shared A. Blomme· 2 shared C. Nixon· 2 shared C. Ntala· 2 shared D. Sumpton· 2 shared G. M. MacKay· 2 shared G. Rodriguez Blanco· 2 shared

Activity by Year

2016-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

M. E. Gleave

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex

S. Lingadahalli, B. E. Fazlioglu, U. B. Altintas, A. Cingoz, E. Tekoglu, I. P. L. Yu, H. Andomat, I. Kulac, T. Morova, K. Xiao, U. M. Dikbas, M. Gleave, L. Fazli, P. Cejas, H. Long, , N. A. Lack

This study shows HOXB13 promotes prostate cancer proliferation by altering chromatin accessibility through interactions with the SWI/SNF complex, particularly in AR-negative castration-resistant prostate cancer.

bioRxiv · Sep 4, 2023 · PreprintCancer Biology

ABI1 regulates transcriptional activity of Androgen Receptor by novel DNA and AR binding mechanism

B. A. Porter, X. Li, N. Arya, F. Zhang, S. H. Y. Kung, L. Fazli, H. Zarni Oo, Y. Li, K. Marincin, K. Kukkonen, H. Urhonen, M. A. Ortiz, A. P. Kemraj, E. Corey, X. Dong, , L. Kotula

This paper identifies ABI1 as an epigenetic regulator of transcriptional homeostasis in AR-driven cancers through novel DNA and AR binding mechanisms.

bioRxiv · May 26, 2023 · PreprintCancer Biology

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

T. Tsujino, T. Takai, K. Hinohara, F. Gui, T. Tsutsumi, X. Bai, C. Miao, C. Feng, B. Gui, S. Sztupinszki, A. Simoneau, N. Xie, L. Fazli, X. Dong, H. Azuma, , L. Jia

This study uses CRISPR screens to identify genetic factors affecting PARP inhibitor sensitivity and resistance in prostate cancer, revealing novel targets and mechanisms.

bioRxiv · Apr 13, 2022 · PreprintCancer Biology

THEM6-mediated lipid remodelling sustains stress resistance in cancer

A. Blomme, C. Peter, E. Mui, G. Rodriguez Blanco, L. M. Mason, L. E. Jamieson, G. H. McGregor, S. Lilla, C. Ntala, R. Patel, M. Thiry, S. H. Kung, C. A. Ford, L. K. Rushworth, D. J. McGarry, , H. Y. Leung

This study identifies THEM6 as a marker of ADT resistance in prostate cancer, showing its role in lipid homeostasis and stress response, and highlights it as a potential therapeutic target.

bioRxiv · Apr 4, 2021Cancer Biology

Schlafen family member 5 (SLFN5) regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer

R. S. Martinez, M. J. Salji, L. Rushworth, C. Ntala, G. Rodriguez Blanco, A. Hedley, W. Clark, P. Peixoto, E. Hervouet, E. Renaude, S. H. Kung, L. C. Galbraith, C. Nixon, S. Lilla, G. M. MacKay, , H. Y. Leung

This study identifies SLFN5 as an AR-regulated biomarker in CRPC that promotes tumour growth by regulating LAT1-mediated mTOR activation.

bioRxiv · Sep 17, 2020 · PreprintCancer Biology

BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma

R. Shrestha, N. Nabavi, Y.-Y. Lin, F. Mo, S. Anderson, S. Volik, H. H. Adomat, D. Lin, H. Xue, X. Dong, R. Shukin, R. H. Bell, B. McConeghy, A. Haegert, S. Brahmbhatt, , C. C. Collins

The paper identifies BAP1 loss as a marker for a distinct immunogenic PeM subtype, suggesting potential therapeutic targets like immune checkpoint inhibitors.

bioRxiv · Dec 13, 2018Cancer Biology

Regulation of eIF4F complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer

M. F. GARRIDO, N. J. MARTIN, C. GAUDIN, F. Commo, N. AL NAKOUZI, L. FAZLI, E. DEL NERY, J. Camonis, F. Perez, S. LERONDEL, A. LE PAPE, H. ABOU-HAMDAN, M. Gleave, Y. Loriot, L. DESAUBRY, , A. CHAUCHEREAU

This study identifies FKBP7 as a molecular chaperone that regulates the eIF4F complex in taxane-resistant prostate cancer, and shows that inhibiting eIF4A can overcome resistance.

bioRxiv · Dec 22, 2016Cancer Biology